gBRCAm HER2-negative high-risk early breast cancer Archives

U.S. FDA approves LYNPARZA as adjuvant treatment for patients with gBRCAm HER2-negative high-risk early breast cancer

Approvals, AstraZeneca, Blockbusters, BRCA mutation, Business, Collaborations, FDA, gBRCAm HER2-negative high-risk early breast cancer, HR+/HER2- advanced or metastatic breast cancer, Merck, New Indications, Oncology, Therapeutics

AstraZeneca and Merck & Co. Inc. announced Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery.

March 11, 2022/by Business Wire